APA

Ritchlin C. T., Kavanaugh A., Merola J. F., Schett G., Scher J. U., Warren R. B., Gottlieb A. B., Assudani D., Bedford-Rice K., Coarse J., Ink B. & McInnes I. B. (20200303). Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. : Lancet (London, England).

Chicago

Ritchlin Christopher T, Kavanaugh Arthur, Merola Joseph F, Schett Georg, Scher Jose U, Warren Richard B, Gottlieb Alice B, Assudani Deepak, Bedford-Rice Kathy, Coarse Jason, Ink Barbara and McInnes Iain B. 20200303. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. : Lancet (London, England).

Harvard

Ritchlin C. T., Kavanaugh A., Merola J. F., Schett G., Scher J. U., Warren R. B., Gottlieb A. B., Assudani D., Bedford-Rice K., Coarse J., Ink B. and McInnes I. B. (20200303). Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. : Lancet (London, England).

MLA

Ritchlin Christopher T, Kavanaugh Arthur, Merola Joseph F, Schett Georg, Scher Jose U, Warren Richard B, Gottlieb Alice B, Assudani Deepak, Bedford-Rice Kathy, Coarse Jason, Ink Barbara and McInnes Iain B. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. : Lancet (London, England). 20200303.